The European Commission is investigating whether Teva has “abusively” blocked or delayed market entry of competitors to the company’s top selling multiple sclerosis drug.
Teva Pharmaceutical Industries Ltd. is the subject of a new antitrust investigation by the European Commission looking at whether the Israeli company artificially extended the market exclusivity of its multiple sclerosis drug Copaxone and also whether it embarked on a campaign to “create a false perception of health risks” with regard to generic competition.
According to the commission, Teva’s actions, if proven, could be an abuse of dominant position, which would infringe Article 102...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
